NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03392428,A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer,https://clinicaltrials.gov/study/NCT03392428,TheraP,COMPLETED,"This open label, randomised, stratified, 2-arm, multicentre, phase 2 trial aims to determine the activity and safety of Lu-PSMA vs cabazitaxel in men with progressive metastatic castration resistant prostate cancer",NO,Cancer of the Prostate|Metastatic Cancer,OTHER: 177Lu-PSMA617|DRUG: Cabazitaxel,"Prostate Specific Antigen response rate (PSA RR), PSA RR defined as the proportion of participants in each group with a PSA reduction of â‰¥ 50% from baseline., Through study completion, on average 4 years","Pain Response (PPI and Analgesic Score), Pain response rate, defined as:

* \>=2 point reduction in PPI score from baseline with no increase in analgesic score; and/or
* \>=50% decrease in analgesic score with no increase in PPI PPI: McGill-Melzack Present Pain Intensity Scale (PPI) Analgesic score: Using Morphine Equivalent Daily Dose (MEDD), Through study completion, on average 4 years|Objective Tumour Response Rate, Objective Tumour Response Rate - defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) divided by the total number of participants (using RECIST 1.1)., Through study completion, on average 4 years|Progression free survival, Progression free survival - the time from randomisation to date of PSA progression (blood samples), pain progression (on PPI) or radiographic progression (PCWG3 for bone and RECIST 1.1 for soft tissue), whichever occurs first, Through study completion, on average 4 years|PSA progression free survival, PSA progression free survival, defined as the time from randomisation to PSA progression, assessed using PCWG3 criteria on blood test results., Through study completion, on average 4 years|Pain progression free survival, Pain progression free survival - defined as the time from randomisation to pain progression (\>=1 point increase on PPI from nadir and \>=25% increase in analgesic score (MEDD) from nadir, OR need for palliative radiotherapy)., Through study completion, on average 4 years|Radiographic progression free survival, Radiographic progression free survival - defined as the time from randomisation to radiographic progression (assessed using PCWG3 criteria for bone lesions and RECIST 1.1 for soft tissue lesions)., Through study completion, on average 4 years|Health-related quality of life, Health-related quality of life, assessed using a composite of the EORTC core quality of life questionnaire (QLQ C-30) and the Patient Disease and Treatment Assessment Form (PDF)., Through study completion, on average 4 years|Overall survival, Overall survival - time from registration to death from any cause or last known follow-up alive., Through study completion, on average 4 years|Frequency and severity of adverse events, Frequency and severity of adverse events (composite), assessed using CTCAE v4.03., From first study dose to 12 weeks after completing study treatment","Tertiary Correlative objectives: Associations between Ga-68 PSMA PET/CT, FDG-PET/CT baseline characteristics, and outcomes, Identification of Ga-68 PSMA PET/CT, FDG-PET/CT markers to predict outcomes., Through study completion, on average 4 years|Tertiary Correlative objectives: Associations between clinical outcomes and possible prognostic and/or predictive biomarkers (tissue and circulating) including ctDNA, Identification of biomarkers to predict outcomes., Through study completion, on average 4 years",Australian and New Zealand Urogenital and Prostate Cancer Trials Group,Australian Nuclear Science and Technology Organisation (ANSTO)|Endocyte|Prostate Cancer Foundation of Australia (PCFA)|Australasian Radiopharmaceutical Trials network (ARTnet)|Movember Foundation,MALE,"ADULT, OLDER_ADULT",PHASE2,201,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,ANZUP 1603,2018-01-29,2019-12-31,2021-12-31,2018-01-08,,2022-06-13,"Liverpool Hospital, Liverpool, New South Wales, 2170, Australia|St Vincent's Hospital, Sydney, New South Wales, 2010, Australia|Royal North Shore Hospital, Sydney, New South Wales, 2065, Australia|Calvary Mater Newcastle Hospital, Waratah, New South Wales, 2298, Australia|Royal Brisbane and Womens Hospital, Brisbane, Queensland, 4029, Australia|Royal Adelaide Hospital, Adelaide, South Australia, 5000, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, 3008, Australia|Austin Hospital, Melbourne, Victoria, 3084, Australia|Monash Moorabbin Hospital, Moorabbin, Victoria, 3165, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, 6450, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, 6009, Australia",
